Table 3.

Response, according to ACR criteria, of subjects in a trial of interferon-β-1a in patients with rheumatoid arthritis

Efficacy end point	Response to placebo (n = 6) No. (%)	Response to interferon (n = 16) No. (%)	P valuea
ITT responder-at-end-point analysis
ACR 20, week 12	1 (17)	3 (19)	0.71
ACR 20, week 24	1 (17)	3 (19)	0.71
ACR 50, week 24	0 (0)	2 (12.5)	0.51
ACR70, week 24	0	0	0
ITT last-observation-carried-forward analysis
ACR 20, week 24	2 (33)	7 (44)	0.52

^aFisher's exact test; ACR 20 (50, 70), 20% (50%, 70%) improvement relative to baseline, according to ACR criteria.